Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Show more

Location: 1150 Veterans Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.nkartatx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

117.8M

52 Wk Range

$1.31 - $8.23

Previous Close

$1.66

Open

$1.68

Volume

505,102

Day Range

$1.64 - $1.70

Enterprise Value

-68.81M

Cash

265.5M

Avg Qtr Burn

-25.2M

Insider Ownership

5.02%

Institutional Own.

91.72%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NKX019 (CAR NK cell therapy) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 1

Data readout

NKX019 Details
Myasthenia gravis

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma

Phase 1

Data readout

Phase 1

Data readout

NKX019 (CAR NK cell therapy) Details
Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis

Phase 1

Data readout

NKX101 (CAR-T targeting NKG2D) Details
Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued